Colorectal cancer (CRC) is heterogeneous, yet current classifications capture this heterogeneity only in part. Here we present a multimodal resource of 1,000 treatment-naïve CRC cases, the largest proteomically profiled CRC cohort to date, integrating deep proteomics, targeted genomics, whole-slide histopathology and c...
A. Qoku, N. Ullrich, F. Miranda et al.· bioRxiv· 0 citations
Survival research in pancreatic ductal adenocarcinoma (PDAC) is limited by the scarcity of datasets linking whole-slide histology with clinical, molecular, and long-term outcome data. We present a retrospective single-centre cohort of 302 patients who underwent PDAC resection at University Medical Center Gottingen. The...
Anh-Tien Nguyen, Mawuko Tettey, J. M. Metsch et al.· 0 citations
Cellular heterogeneity in pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for disease prognosis and limits the effectiveness of therapeutic strategies implemented in recent multicenter subtype-based clinical trials worldwide. A hallmark of PDAC is extensive intratumoral heterogeneity, which is la...
Xue-Yan Wu, L. Klein, M. Tu et al.· Cancer Research· 0 citations
Abstract Pancreatic ductal adenocarcinoma (PDAC) remains a formidable clinical challenge. Next-generation protein arginine methyltransferase 5 (PRMT5) inhibitors show promising clinical results in a subset of PDACs with codeletion of the tumor-suppressor CDKN2A and the methylthioadenosine phosphorylase (MTAP) gene, but...
Valentina Spielmann, Jonas Buchloh, Selen Selcen et al.· Cancer Research Communicatio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
